Blunt Roy sold (to issuer) $86K of THC

Blunt Roy sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · Blunt Roy
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Because the transaction is a small director sale and explicitly coded as a sale to the issuer, it is more consistent with routine liquidity/buyback participation than a fundamental change; traders may treat it as sentiment noise unless paired with other negative signals.

02

Market read

Monitor for patterns, but the disclosed transaction alone is unlikely to drive a sustained move in THC.

03

What to watch

The code indicates sale to the issuer (often buyback mechanics), and the filing provides no rationale or broader context for interpreting intent.

Relevance 6/10Timing: Immediate for monitoring (Form 4 filed 2026-05-26, transaction dated 2026-05-22), but not a catalyst.

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reported via EDGAR.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Blunt Roy sold 493 shares to the issuer at $173.78/share, reducing holdings to 5,189 shares (SEC Form 4).

Expected impact

Likely minimal price impact; any reaction should be muted unless accompanied by unusual volume or broader insider selling trends.

Evidence & confidence

This is a routine Form 4 insider transaction with no accompanying operational or financial catalyst described in the filing details provided.

Market effects

No sector read-across; this is company-specific insider transaction disclosure only.

None indicated.

None indicated.

Counterpoint

If the sale is part of repeated insider selling, it could be a mild bearish signal despite the issuer-sale code.

Key entities

  • Tenet Healthcare Corp

    Subject of the SEC Form 4 insider transaction; director sold 493 shares at $173.78/share.

  • Blunt Roy

    Reported insider who sold shares to the issuer; holdings after transaction: 5,189 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.